Introduction
Wilms tumor (WT), a childhood kidney cancer which occurs in approximately 1 per 10 000 live births, is responsible for about 400 tumors per year in the USA (Young et al., 1986) . The majority of cases are diagnosed by 6 years of age, although rare cases have been documented in adolescents and adults. The inactivation of tumor-suppressor genes, by a two-hit mechanism involving mutations and loss of heterozygosity (LOH), appears to be a common event in the development of Wilms tumors (Knudson and Strong, 1972) . Several chromosomal regions, including 1p, 11p13, 11p15 and 16q show consistent genetic changes in tumor tissue (Grundy et al., 1995) , suggesting that multiple suppressor genes are likely to be involved in the etiology of the disease. The association of Wilms tumor with aniridia, genito-urinary abnormalities and mental retardation (the WAGR syndrome), and cytogenetically visible alterations of chromosome 11p13 led to the identi®cation of the WT1 locus (Franke et al., 1979) . The characterization of homozygous deletions observed in individuals with WAGR and in tumors from sporadic WT patients enabled the isolation of the WT1 gene Huang et al., 1990; Call et al., 1990; Gessler et al., 1990) . Analyses of WT1 mutations in patients with DenysDrash syndrome (intersex disorders and nephropathy coupled with Wilms tumor), established the WT1 gene as an important tumor suppressor which also played a crucial role in urogenital development (Pelletier et al., 1991) . However, extensive mutational analyses of WT1 in sporadic Wilms tumors indicates that mutations occur at a frequency of only about 10% (Varanasi et al., 1994) . A second locus on chromosome 11p15 (WT2) shows a high frequency of loss of heterozygosity in Wilms tumors (Coppes et al., 1992) . Furthermore, linkage analysis and cytogenetic rearrangements have mapped the gene(s) for Beckwith-Weidemann syndrome (BWS) to 11p15.5 (Ping et al., 1989) . BWS is characterized by hemihypertrophy, macroglossia, umbilical hernia, and an increased risk for developing childhood cancers including Wilms tumors (SoteloAvila and Gooch, 1976) . Functional studies using chromosome mediated gene transfer into the rhabdoid tumor cell line G401 have also been used to map a tumor suppressor locus to 11p15 (Reid et al., 1996) . Since positional cloning eorts to identify the target genes on 11p15 are complicated by the large size of this region (*10 Mb) and complexity of LOH, we have re®ned the mapping of the WT2 locus by performing a detailed LOH analysis of the 11p15.5 ± 11p15.4 region using a high-density marker analysis of 38 informative tumor DNAs. The earlier described WT2 locus, has been re®ned from 2 Mb (Besnard-Guerin et al., 1996) to *800 kb. We have also identi®ed a second novel locus of approximately 336 kb, that is proximal to WT2 and is also frequently lost in Wilms tumors. Thus two distinct regions of LOH on chromosome 11p15, appear to play a role in the development of Wilms tumors.
Results
To identify the smallest common deleted region on chromosome 11p15 in Wilms tumors, thirty eight tumor DNAs and matching constitutional DNA samples were assessed for LOH at 15 chromosome 11p15-speci®c polymorphic loci. These markers encompass the chromosomal sub-regions 11p15.5 ± 11p15.4, estimated to be *8 ± 10 Mb (James et al., 1994) . LOH occurred in at least one marker on the short arm of chromosome 11 in 16 of 38 (43% (Figure 1 ) de®ne the LOH breakpoints and provide a critical description of the region. Two regions of LOH at 11p15 can be identi®ed. The telomeric region (region 1) is encompassed by the markers TH and D11S1288 and is de®ned by the LOH breakpoints in tumors 28 and 40 as identi®ed using Genescan (Figure 2 ). Tumor 28 retained heterozygosity for HRAS, ECS1, TH and D11S1318, but showed LOH for the markers D11S1288 and D11S860. ECS1, is a novel gene that we have recently mapped to the 11p15 region (Paris et al., in preparation). Tumor 28 was non-informative for the marker IGF2 but retained heterozygosity for the proximal markers D11S988, HBB, D11S1760, D11S1338, D11S1323, D11S1997, D11S866 and D11S1331. Tumor 40 showed LOH at markers ECS1, TH and D11S1318 and was non-informative for the markers HRAS and IGF2 and for the proximal marker D11S860. This tumor was heterozygous for all the remaining markers including D11S1288. Tumors 28 and 40, therefore, re®ne the LOH Region 1 to a distance of *800 kb between the markers D11S1318 and D11S1288. Importantly, these results narrow the region containing this tumor suppressor gene from 2 Mb reported earlier (Besnard-Guerin et al., 1996) to *800 kb.
The more centromeric region of LOH (region 2) is de®ned by breakpoints in the tumors 67 and 15 (Figures 1 and 2 ). Tumor 67 was heterozygous for the markers HRAS, ECS1, TH, D11S1318, D11S1288, D11S988 and HBB and non-informative for D11S860 and IGF2. This tumor showed LOH for the markers D11S1760 and D11S1338 and was heterozygous for the remaining proximal markers. Tumor 15 showed LOH at the markers D11S1323, D11S1997, D11S866 and D11S1331. This tumor was non-informative for the markers HRAS, IGF2, D11S1318 and was heterozygous at all the remaining markers. It is notable that tumors 67 and 15 exhibit LOH at either D11S1338 or D11S1323. This suggests that region 2 is within the interval that spans the markers D11S1338 ± D11S1323 a distance estimated to be *336 kb (James et al., 1994) . We have mapped integrin-linked kinase (p59ILK) on the yeast arti®cial chromosome (YAC) 847a12 that harbors the markers D11S1338 and D11S1323. PCR ampli®cation of the DNA from the YAC 847a12 with several dierent p59ILK primers produced the expected length fragments (data not shown). No ampli®cation products were observed from a BAC DNA speci®c for the marker D11S1323 or from yeast DNA. Thus p59ILK is a candidate tumor suppressor gene for this locus. p59ILK was previously mapped to the CALC-HBBC region on chromosome 11p15 (Hannigan et al., 1997) .
The data described indicate the presence of two distinct regions of LOH within 11p15.5 ± 15.4. Five of the tumors in the group studied, examples of which are 12, 19, 25, 35 and 45 (Figure 1 ), appeared to have lost both of the LOH regions on the chromosome 11p arm. However, only tumors 35 and 45 in this group appeared to have also lost the 11p13 markers (Coppes et al., 1992) suggesting the loss of the entire 11p arm in these tumors.
Discussion
We have identi®ed two distinct regions on chromosome 11p15 that are subject to LOH in Wilms tumors. The two LOH regions overlap with the LOH map that we have previously described for breast cancer (Karnik et al., 1998). LOH involving region 1 coincides with regions implicated in the pathogenesis of rhabdomyosarcoma (Besnard-Guerin et al., 1996; Sait et al., 1994) , breast cancer (Karnik et al., 1998; Winquist et al., 1995) , ovarian carcinoma (Viel et al., 1992) , stomach adenocarcinoma (Baa et al., 1996) and with a region conferring tumor suppressor activity previously identi®ed by genetic complementation experiments (Reid et al., 1996; Koi et al., 1993) . Inversions and translocations at chromosome band 11p15.5, associated with Beckwith-Wiedemann syndrome and malignant rhabdoid tumors (Sait et al., 1994; Hoovers et al., 1995) overlap with both regions of LOH in this study. Importantly, we have more precisely re®ned the location of the putative tumor suppressor gene in region 1 from 2 Mb (Besnard-Guerin et al., 1996) to 800 kb. As illustrated in Figure 3 , several genes that map to this region are subject to allele-speci®c imprinting (Reid et al., 1997) thereby raising the possibility that the tumor suppressor gene that maps to 11p15.5 may be imprinted in a tissue-speci®c manner. Given the size of LOH region 1, it is possible that a single pleiotropic gene rather than a cluster of genes may play a role in the genesis of dierent cancers, possibly at dierent stages of tumor development and progression. More extensive analysis and isolation of the target gene that maps to this region will be important to establish whether loss or alteration of the same or dierent genes is involved in each of these cases. p57KIP2 and NAP2 (Reid et al., 1997) are potential tumor suppressor candidate genes that map to region 1. However, single strand conformation analysis and direct sequencing of Wilms tumors failed to reveal mutations in these genes (Karnik et al., unpublished observations) .
In addition to the previously described WT2 locus, we have identi®ed a second region of LOH (region 2) at 11p15 in Wilms tumors. This novel LOH locus in Wilms tumors, is de®ned by markers D11S1338 ± D11S1323, which spans a distance of *336 kb and is centromeric to the putative WT2 gene. We have narrowed this region from 5 ± 10 Mb (Tran and Newsham, 1996; Ali et al., 1987) to *336 kb, with the highest incidence of LOH, at the marker D11S1338. Integrin-linked kinase (p59ILK) was earlier shown to map to the CALC-HBBC region and was shown to induce anchorage-independent growth and a tumorigenic phenotype in rodents (Hannigan et al., 1997) . We have re®ned the map location of p59ILK, and placed this gene on the yeast arti®cial chromosome (YAC) 847a12, that harbors the markers D11S1338 and D11S1323. Thus, p59ILK is a potential tumor suppressor candidate for region 2.
These ®ndings suggest the presence of two distinct tumor suppressor loci on chromosome 11p15 that appear to play a role in the development of Wilms tumors. The ®ne-mapping of these loci should lead to the cloning of the target genes and the establishment of mechanisms that contribute to the development of Wilms tumor and other childhood and adult cancers.
Materials and methods
Patient materials and preparation of genomic DNA Constitutional and tumor DNA from patients were obtained for 38 Wilms tumor cases as described previously (Coppes et al., 1992) . Thirty-three patients had unilateral Wilms tumors and ®ve had bilateral disease. The median age at diagnosis was 3 years (range, 3 months to 14.7 years). There were 18 male and 20 female patients. Constitutional DNA was obtained from peripheral blood leukocytes, lymphoblastoid cell lines, primary skin fibroblast cultures, or normal kidney tissue. Tumor tissues taken for DNA and RNA analyses were directly snapfrozen in liquid nitrogen.
Microsatellite polymorphisms and primers
DNA sequences¯anking polymorphic loci on chromosome 11p15.5 were obtained from the Genome Data Base (GDB). The sequence analysis and characterization of the new gene, ECS1 will be described elsewhere (Paris et al., in preparation). Dye labeled (FAM or HEX from Applied Biosystems) primers were either obtained from Research Genetics (Huntsville, Alabama) or synthesized as described earlier (Karnik et al., 1995) . One primer in each pair was uorescently labeled so that only one DNA strand was detected on the gel.
Polymerase Chain Reaction (PCR) and analysis of PCR products using genescan software PCR of the DNA sequences was performed as described (Karnik et al., 1995) . PCR products were analysed on Seaquate 6% DNA sequencing gels (Garvin, OK) in 16TBE buer in a Model 373A automated¯uorescent DNA sequencer (Applied Biosystems) which is a four color detection system. One ml of each PCR reaction was combined with 4 ml formamide and 0.5 ml of a fluores- Figure 3 Schematic representation of regions on chromosome 11p15.5 ± 15.4 harboring potential tumor suppressor and/or disease loci described in the present study and by other groups in Wilms tumor, Beckwith-Wiedemann syndrome, Rhabdomyosarcoma, breast cancer, non small cell lung carcinoma and stomach adenocarcinoma. Several imprinted genes that map to the WT2 region are boxed cent size marker (ROX 350, Applied Biosystems). The gel was run for 6 h at 30 W. During electrophoresis, thē uorescence detected in the laser scanning region was collected and stored using the Genescan Collection software (Applied Biosystems). The¯uorescent gel data collected during the run was automatically analysed by the Genescan Analysis program (Applied Biosystems) at the end of each run. Each¯uorescent peak was quantitated in terms of size (in base pairs), peak height and peak area.
LOH analysis with Genescan
To detect the presence and extent of LOH in the tumors, we analysed constitutional and tumor DNA from each patient for CA repeat sequences using¯uorescent technology (Karnik et al., 1995) . In most Wilms tumors, LOH was identi®ed by the complete loss of one allele. The ratio of alleles was calculated for each normal and tumor sample and then the tumor ratio was divided by the normal ratio, i.e. T1 : T2/N1 : N2, where T1 and N1 are the area values of the shorter length allele and T2 and N2 are area values of the longer allele product peak for tumor and normal respectively. At least three independent sets of results were used to con®rm LOH in each tumor.
